TATA-Binding Protein-Based Virtual Screening of FDA Drugs Identified New Anti-Giardiasis Agents

Carlos Gaona-López,Domingo Méndez-Álvarez,Adriana Moreno-Rodríguez,Juan Luis Bautista-Martínez,José Antonio De Fuentes-Vicente,Benjamín Nogueda-Torres,Itzhel García-Torres,Gabriel López-Velázquez,Gildardo Rivera

DOI: https://doi.org/10.3390/ijms25116238

IF: 5.6

2024-06-06

International Journal of Molecular Sciences

Abstract:Parasitic diseases, predominantly prevalent in developing countries, are increasingly spreading to high-income nations due to shifting migration patterns. The World Health Organization (WHO) estimates approximately 300 million annual cases of giardiasis. The emergence of drug resistance and associated side effects necessitates urgent research to address this growing health concern. In this study, we evaluated over eleven thousand pharmacological compounds sourced from the FDA database to assess their impact on the TATA-binding protein (TBP) of the early diverging protist Giardia lamblia, which holds medical significance. We identified a selection of potential pharmacological compounds for combating this parasitic disease through in silico analysis, employing molecular modeling techniques such as homology modeling, molecular docking, and molecular dynamics simulations. Notably, our findings highlight compounds DB07352 and DB08399 as promising candidates for inhibiting the TBP of Giardia lamblia. Also, these compounds and DB15584 demonstrated high efficacy against trophozoites in vitro. In summary, this study identifies compounds with the potential to combat giardiasis, offering the prospect of specific therapies and providing a robust foundation for future research.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to find new drugs against Giardiasis. Specifically, researchers evaluated the effects of FDA - approved drugs on the TATA - binding protein (TBP) in *Giardia lamblia* through virtual screening of the FDA - approved drug library, in the hope of discovering potential drugs that can inhibit the parasite's TBP. Due to the problems of drug resistance and side effects of existing treatment drugs, this study aims to provide new treatment options for combating Giardiasis. ### Research Background - **Prevalence of Giardiasis**: Giardiasis is a globally distributed parasitic disease, causing an estimated more than 300 million cases annually, especially in developing countries. - **Problems of Existing Drugs**: Currently, drugs used to treat Giardiasis (such as 5 - nitroimidazole derivatives like metronidazole) are effective but have serious side effects and drug resistance has already emerged. - **New Therapeutic Targets**: Transcription factors, especially the TATA - binding protein (TBP), are considered as potential targets for developing new drugs because of their conservation and low mutation rate in different species. ### Research Methods - **Virtual Screening**: Researchers screened more than 11,000 compounds from the FDA - approved drug library and used molecular modeling techniques (such as homology modeling, molecular docking, and molecular dynamics simulation) to evaluate the inhibitory effects of these compounds on Giardia TBP. - **Selection Criteria**: Compounds that meet the requirements were screened out through Lipinski's Rule of Five, and their interactions with human TBP were further evaluated to ensure their selectivity. ### Main Findings - **Potential Candidate Drugs**: The study found that several compounds have high selectivity and inhibitory effects, especially DB07352 and DB08399. These two compounds showed high effectiveness against Giardia trophozoites in vitro experiments. - **Molecular Dynamics Analysis**: Through molecular dynamics simulation, it was confirmed that DB07352 and DB08399 stably bind to Giardia TBP and unstably bind to human TBP, indicating their high selectivity. ### Conclusions - **Potential New Drugs**: This study has identified some compounds with potential anti - Giardiasis activity, providing a basis for developing new treatment methods. - **Future Research Directions**: Further in vivo experiments and clinical trials will verify the actual efficacy and safety of these compounds. In general, this paper successfully discovered several potential anti - Giardiasis drugs through virtual screening and molecular modeling techniques, providing new hope for solving the problems of drug resistance and side effects of current treatment drugs.

TATA-Binding Protein-Based Virtual Screening of FDA Drugs Identified New Anti-Giardiasis Agents

Synthesis, in Vitro and in Vivo Biological Evaluation of Dihydroartemisinin Derivatives with Potential Anti-Toxoplasma Gondii Agents.

Structure-Based Virtual Screening, Insilico Docking, ADME Prediction, and Molecular Dynamics Studies for Identification of Potential NMT Inhibitors Against Malaria

Repositioning FDA-Approved Drug Against Chagas Disease and Cutaneous Leishmaniosis by Structure-Based Virtual Screening

Virtual Screening of FDA-Approved Drugs against Triose Phosphate Isomerase from Entamoeba histolytica and Giardia lamblia Identifies Inhibitors of Their Trophozoite Growth Phase

Giardia lamblia G6PD::6PGL Fused Protein Inhibitors Decrease Trophozoite Viability: A New Alternative against Giardiasis

Putative Inhibitor of TcCYP51 from a Library of Approved Drugs: A Virtual Screening Study

Structure-Based Screening of Plasmodium berghei Glutathione S-Transferase Identifies CB-27 as a Novel Antiplasmodial Compound

Identification of fungal natural products with potent inhibition in Toxoplasma gondii

Click chemistry-facilitated comprehensive identification of proteins adducted by antimicrobial 5-nitroimidazoles for discovery of alternative drug targets against giardiasis

Investigation on Anti‐plasmodial Agents Against wild‐type PfDHFR Through In Silico Computational Tools

Anti-parasitic drug discovery against Babesia microti by natural compounds: an extensive computational drug design approach

Antiprotozoan lead discovery by aligning dry and wet screening: prediction, synthesis, and biological assay of novel quinoxalinones

Expanding the antiprotozoal activity and the mechanism of action of n-butyl and iso-butyl ester of quinoxaline-1,4-di-N-oxide derivatives against Giardia lamblia, Trichomonas vaginalis, and Entamoeba histolytica. An in vitro and in silico approach

Molecular modelling and experimental validation identified a new therapeutic inhibitor of toxoplasmosis

High Throughput Repurposing Screen Reveals Compounds with Activity Against Toxoplasma gondii Bradyzoites

In Vitro Efficacy of Next Generation Dihydrotriazines and Biguanides Against Babesiosis and Malaria Parasites

A Computational Approach Using α-Carbonic Anhydrase to Find Anti-Trypanosoma cruzi Agents

High-Throughput Screening of Entamoeba Identifies Compounds Which Target Both Life Cycle Stages and Which Are Effective Against Metronidazole Resistant Parasites

Identification of potential inhibitors against Inosine 5'-Monophosphate Dehydrogenase of Cryptosporidium parvum through an integrated in silico approach

Onchocerciasis Drug Discovery: In Vitro Evaluation of FDA-Approved Drugs against Onchocerca gutturosa in Gambia